The Related Research Of Biologicafactors Before And After Neoadjuvant Chemotherapy

Breast cancer is one of the primary malignant tumor of women’s health, and showing anincreasing incidence of. Worldwide each year about1.2million women of breast cancer,accounting for18%of all tumors of the female. Breast cancer5-year survival rate was50%to60%, nearly50%of patients with recurrence and metastasis in patients with advancedbreast cancer survival rate is only18~30months. The incidence of breast cancer is acomplex biological process as the result of the interaction of genetic and environmentalfactors. Breast cancer treatment is toward individualized, standardized treatment direction,chemotherapy is still one of the most important means to occupy an important position inthe comprehensive treatment of breast cancer. How the effect of chemotherapy is directlyrelated to the prognosis and survival of breast cancer patients. Before and after surgery, theapplication of systemic chemotherapy is still the effective way to improve prognosis andincrease the survival rate. The prognosis of breast cancer chemotherapy is more difficult,the application of more conventional prognosis indicators include tumor size, degree ofdifferentiation, invasion, regional lymph node metastasis. Recently neoadjuvantchemotherapy has been developed rapidly. Neoadjuvant chemotherapy which is treatedwith surgery or radiation therapy prior to the implementation of systemic chemotherapy,has become the standard treatment of advanced breast cancer. Ki-67is a tumorproliferation associated nuclear antigen. Ki-67expression related to cell cycle canaccurately reflect the activity of tumor cell proliferation and tumor progression, metastasis.Study found that Ki-67expression in the well-differentiated adenocarcinoma was moresignificantly increased than in poorly differentiated adenocarcinoma, indicating that theKi67staining positive is associated with histological grade. Ki67in breast cancer relatedto the development is an adverse prognostic factors, which is an important reference value for the diagnosis of breast cancer treatment and prognostic evaluation. Topo II α is a DNAtopoisomerase II alpha.For the treatment of breast cancer Topo II alpha as the role of theanthracycline anticancer drugs target, its low expression levels can often cause the bodyresistance, considering that Topo II alpha can be used to predict patients withanthracyclinethe efficacy and prognosis. C-erbB-2which often change in human tumor isan oncogene. In recent years many studies have shown that it has been involved intumorigenesis and development is a new target for cancer prevention and treatment.C-erbB-2overexpression in breast cancer is associated with cancer division, histologyclass, endocrine treatment response and prognosis factors. In addition, there are manybiological factors used clinically, such as ER COX-2and MMP, PR, etc. has been usedclinically test to help doctors to determine the prognosis after treatment, and clinicaltreatment. This experiment by hospital patients with breast cancer neoadjuvantchemotherapy using paclitaxel plus anthracycline anticancer drugs, study before and afterchemotherapy in patients with changes and clinical significance of C-erbB-2, Topo II alphaand Ki-67and its expression in neoadjuvant chemotherapy, efficacy and clinical stage,through a comparative analysis, to evaluate the clinical predictive value of neoadjuvantchemotherapy for breast cancer.